Site operations

Protocol deviations: why they are rising and how sites reduce them

By TrialNotice · Updated
Inspector reading a document across a conference table from a site director, with regulatory binders between them
Short answerProtocol deviations are common and rising with protocol complexity: Tufts CSDD found Phase II and III protocols average 75 and 119 deviations, involving nearly a third of enrolled patients, and over 40% of patients in oncology trials. More endpoints, more procedures per visit, and more countries all predict more deviations. Sites reduce them with visit checklists built from the protocol, prescreening against the deciding criteria, and fast retraining after amendments.

How common are deviations?

  • Phase II protocols average 75 deviations and Phase III 119, involving nearly one third of all enrolled patients (Tufts CSDD).
  • Oncology trials have the highest rates, affecting more than 40% of enrolled patients (Tufts CSDD); combined Phase II and III oncology protocols involve 47% of volunteers (Applied Clinical Trials).
  • SCRS's 2025 survey reports deviations rising along with endpoints and procedures (Clinical Leader).

What drives them?

Complexity. The number of endpoints, procedures per visit, and countries were positively associated with deviations, and more investigative sites meant more deviations (Tufts CSDD). Deviation incidence also correlated with longer trial milestone durations (Applied Clinical Trials). Amendments add risk: sites may run different protocol versions for a mean of 215 days during an amendment cycle (IntuitionLabs, citing Tufts CSDD).

Why do they matter to a site?

Failure to follow the investigational plan is among the most common FDA inspection findings at investigator sites (FDA). Deviations also show up on sponsor scorecards and can cost a site future studies.

How do sites reduce them?

  1. Visit checklists built from the schedule of assessments, per visit.
  2. Visit window tracking with reminders before windows close.
  3. Prescreening against the deciding criteria, so ineligible patients are never enrolled.
  4. Same week retraining after each amendment, with version control on every form.
  5. Monthly deviation review to spot repeat causes.

Where do eligibility deviations start?

Often at recruitment. Patients enrolled on incomplete history are more likely to turn out ineligible later. Referrals from physicians who know a patient's diagnosis, medications, and history arrive with better information, which lowers both screen failures and eligibility deviations. See how to lower screen failure rates.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Getz K. et al., "Benchmarking Protocol Deviations and Their Variation by Major Disease Categories," Therapeutic Innovation & Regulatory Science (2022)
  2. Applied Clinical Trials, "Quantifying Protocol Deviation Experience by Clinical Phase" (Tufts CSDD)
  3. Clinical Leader, "Endpoints, Procedures, And Deviations Are On The Rise" (2025 SCRS Landscape Survey Report)
  4. FDA, Bioresearch Monitoring (BIMO) Fiscal Year 2023 Metrics
  5. IntuitionLabs, "Clinical Trial Protocol Amendments: Frequency, Cost and Delay Data" (citing Tufts CSDD)

Keep reading

Three clinical research coordinators laughing over coffee at a table in a sunny staff break room
Site operations

Why research coordinators leave, and how sites keep them

Site turnover runs 35% to 61% a year, and 85% of departing staff go to sponsors and CROs. Here is why coordinators leave, what turnover costs a site, and what keeps them.

 Tired coordinator in navy scrubs rubbing her eyes at a desk with two monitors and a stack of binders
Site operations

Sponsor training burden: where coordinator hours really go

Sites average 17.5 hours per study per month on training, and 65% of mandatory training is considered redundant. Here is the data, the industry efforts to cut it, and what sites can do now.

 Coordinator moving a sticky note on a crowded study calendar board in a research office
Site operations

Why study startup takes so long, and where sites lose weeks

Study startup averages 31.4 weeks from site identification, and the contract and budget stages take the largest share. Here is where the time goes and which delays a site controls.